XE7C Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Cardiff Oncology Inc

Watchlist Manager

Watchlist

Price: 1.363 EUR -4.69% Market Closed

Market Cap: €61m

C	Cardiff Oncology Inc SWB:XE7C	US
	Kirkland's Inc NASDAQ:TBHC	US
	Donskoy Zavod Radiodetaley OAO MOEX:DZRDP	RU

Profitability Summary

Cardiff Oncology Inc's profitability score is 40/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-8.256%

Negative 3Y Average Operating Margin

-8.675%

Operating Margin is Increasing

-10.479% > -8.256%

Negative Net Margin

-7.736%

Negative 3Y Average Net Margin

-8.031%

Net Margin is Increasing

-9.990% > -7.736%

Negative Free Cash Flow Margin

-6.403%

Negative 3Y Average Free Cash Flow Margin

-6.581%

Free Cash Flow Margin is Increasing

-8.482% > -6.403%

Negative ROE

-71%

Negative 3Y Average ROE

Exceptional 3Y Average ROIC

131%

ROIC is Increasing

-541% > 2.404%

View All

Hide

Collapse

40 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.